vs
Side-by-side financial comparison of MANGOCEUTICALS, INC. (MGRX) and Progyny, Inc. (PGNY). Click either name above to swap in a different company.
Progyny, Inc. is the larger business by last-quarter revenue ($318.4M vs $94.4K, roughly 3374.3× MANGOCEUTICALS, INC.). Progyny, Inc. runs the higher net margin — 3.9% vs -2935.1%, a 2939.0% gap on every dollar of revenue. On growth, Progyny, Inc. posted the faster year-over-year revenue change (6.7% vs -10.3%). Over the past eight quarters, Progyny, Inc.'s revenue compounded faster (7.0% CAGR vs -33.6%).
MANGOCEUTICALS, INC. is a men's health and personal care company that develops, manufactures, and distributes science-backed consumer products, including dietary supplements, skincare, and hair care solutions targeted at common male wellness needs. It mainly operates in the U.S. market, selling via direct-to-consumer e-commerce platforms and select retail partners, prioritizing accessible, transparent wellness offerings for adult male consumers.
Progyny, Inc. is a leading fertility and family building benefits provider operating primarily in the United States. It partners with employers to offer benefits including in vitro fertilization, fertility preservation, adoption assistance, and surrogacy support, serving millions of members across diverse industry segments.
MGRX vs PGNY — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $94.4K | $318.4M |
| Net Profit | $-2.8M | $12.5M |
| Gross Margin | 50.3% | 24.1% |
| Operating Margin | -389.7% | 4.8% |
| Net Margin | -2935.1% | 3.9% |
| Revenue YoY | -10.3% | 6.7% |
| Net Profit YoY | -42.1% | 18.5% |
| EPS (diluted) | $0.38 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $94.4K | $318.4M | ||
| Q3 25 | $84.2K | $313.3M | ||
| Q2 25 | $168.1K | $332.9M | ||
| Q1 25 | $109.3K | $324.0M | ||
| Q4 24 | $105.2K | $298.4M | ||
| Q3 24 | $133.4K | $286.6M | ||
| Q2 24 | $163.2K | $304.1M | ||
| Q1 24 | $214.1K | $278.1M |
| Q4 25 | $-2.8M | $12.5M | ||
| Q3 25 | $-7.6M | $13.9M | ||
| Q2 25 | $-5.4M | $17.1M | ||
| Q1 25 | $-4.8M | $15.1M | ||
| Q4 24 | $-1.9M | $10.5M | ||
| Q3 24 | $-2.0M | $10.4M | ||
| Q2 24 | $-2.4M | $16.5M | ||
| Q1 24 | $-2.4M | $16.9M |
| Q4 25 | 50.3% | 24.1% | ||
| Q3 25 | 60.4% | 23.2% | ||
| Q2 25 | 53.5% | 23.7% | ||
| Q1 25 | 56.8% | 23.4% | ||
| Q4 24 | 76.1% | 21.3% | ||
| Q3 24 | 62.0% | 20.7% | ||
| Q2 24 | 42.8% | 22.5% | ||
| Q1 24 | 68.8% | 22.4% |
| Q4 25 | -389.7% | 4.8% | ||
| Q3 25 | -8953.5% | 6.9% | ||
| Q2 25 | -3134.0% | 7.3% | ||
| Q1 25 | -4440.0% | 7.5% | ||
| Q4 24 | -1594.0% | 5.3% | ||
| Q3 24 | -1318.2% | 4.3% | ||
| Q2 24 | -1329.1% | 6.8% | ||
| Q1 24 | -1105.9% | 6.7% |
| Q4 25 | -2935.1% | 3.9% | ||
| Q3 25 | -9042.8% | 4.4% | ||
| Q2 25 | -3221.6% | 5.1% | ||
| Q1 25 | -4427.4% | 4.6% | ||
| Q4 24 | -1851.2% | 3.5% | ||
| Q3 24 | -1499.0% | 3.6% | ||
| Q2 24 | -1465.4% | 5.4% | ||
| Q1 24 | -1105.9% | 6.1% |
| Q4 25 | $0.38 | $0.14 | ||
| Q3 25 | $-0.69 | $0.15 | ||
| Q2 25 | $-0.57 | $0.19 | ||
| Q1 25 | $-1.29 | $0.17 | ||
| Q4 24 | $-0.79 | $0.12 | ||
| Q3 24 | $-1.14 | $0.11 | ||
| Q2 24 | $-1.37 | $0.17 | ||
| Q1 24 | $-1.50 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.5M | $112.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.2M | $516.0M |
| Total Assets | $16.1M | $742.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.5M | $112.2M | ||
| Q3 25 | $481.3K | $134.0M | ||
| Q2 25 | $101.0K | $132.5M | ||
| Q1 25 | $76.5K | $109.2M | ||
| Q4 24 | $58.7K | $162.3M | ||
| Q3 24 | $73.9K | $91.5M | ||
| Q2 24 | $490.2K | $95.0M | ||
| Q1 24 | $15.3K | $115.0M |
| Q4 25 | $15.2M | $516.0M | ||
| Q3 25 | $15.7M | $560.0M | ||
| Q2 25 | $19.2M | $515.0M | ||
| Q1 25 | $20.3M | $467.2M | ||
| Q4 24 | $13.9M | $422.1M | ||
| Q3 24 | $13.4M | $434.9M | ||
| Q2 24 | $13.8M | $456.2M | ||
| Q1 24 | $-958.4K | $571.6M |
| Q4 25 | $16.1M | $742.4M | ||
| Q3 25 | $16.5M | $795.2M | ||
| Q2 25 | $20.8M | $761.0M | ||
| Q1 25 | $21.8M | $730.3M | ||
| Q4 24 | $15.4M | $607.1M | ||
| Q3 24 | $14.8M | $660.0M | ||
| Q2 24 | $15.2M | $698.6M | ||
| Q1 24 | $301.4K | $794.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $54.2M |
| Free Cash FlowOCF − Capex | — | $48.6M |
| FCF MarginFCF / Revenue | — | 15.3% |
| Capex IntensityCapex / Revenue | — | 1.8% |
| Cash ConversionOCF / Net Profit | — | 4.34× |
| TTM Free Cash FlowTrailing 4 quarters | — | $191.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $54.2M | ||
| Q3 25 | $-1.2M | $50.7M | ||
| Q2 25 | $-1.3M | $55.5M | ||
| Q1 25 | $-2.3M | $49.8M | ||
| Q4 24 | $-1.1M | $52.2M | ||
| Q3 24 | $-1.2M | $44.5M | ||
| Q2 24 | $-1.6M | $56.7M | ||
| Q1 24 | $-991.1K | $25.7M |
| Q4 25 | — | $48.6M | ||
| Q3 25 | — | $46.0M | ||
| Q2 25 | — | $50.2M | ||
| Q1 25 | — | $47.0M | ||
| Q4 24 | — | $50.3M | ||
| Q3 24 | — | $42.7M | ||
| Q2 24 | — | $55.8M | ||
| Q1 24 | — | $24.9M |
| Q4 25 | — | 15.3% | ||
| Q3 25 | — | 14.7% | ||
| Q2 25 | — | 15.1% | ||
| Q1 25 | — | 14.5% | ||
| Q4 24 | — | 16.8% | ||
| Q3 24 | — | 14.9% | ||
| Q2 24 | — | 18.4% | ||
| Q1 24 | — | 8.9% |
| Q4 25 | — | 1.8% | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | — | 1.6% | ||
| Q1 25 | — | 0.9% | ||
| Q4 24 | — | 0.6% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | — | 4.34× | ||
| Q3 25 | — | 3.65× | ||
| Q2 25 | — | 3.24× | ||
| Q1 25 | — | 3.31× | ||
| Q4 24 | — | 4.95× | ||
| Q3 24 | — | 4.27× | ||
| Q2 24 | — | 3.44× | ||
| Q1 24 | — | 1.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MGRX
Segment breakdown not available.
PGNY
| Fertility Benefit Services | $208.6M | 66% |
| Pharmacy Benefit Services | $109.8M | 34% |
